Haemonetics Corporation (HAE) Stock Analysis

Haemonetics' Hospital segment — VASCADE vascular closure devices, the TEG 6s hemostasis system, Cell Saver Elite+, and SavvyWire — generated 44.1% of FY2026 net revenues, with Plasma (NexSys PCS, NexLynk DMS) at 39.3% and Blood Center at 16.6%. In Q4 FY2026, the company received FDA 510(k) clearance for NexSys PCS with Persona PLUS technology and FDA approval to expand the VASCADE MVP XL indication to larger-bore sheaths. Products reach approximately 90 countries through a direct sales force and independent distributors across roughly 87 markets; the top-ten customers generated approximately 44% of net revenues, with one Plasma customer at 13%.

Haemonetics generates revenue through device sales and related single-use disposables, with the recurring disposable component providing volume visibility tied to plasma donation and procedure rates. The Plasma segment serves a small pool of vertically integrated biopharmaceutical customers — including Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary, and CSL — that operate dedicated collection centers and demand yield improvements that lower per-unit collection costs. In January 2025, the company divested the Whole Blood product line within Blood Center, concentrating resources in Plasma and Hospital. The Hospital segment competes for value analysis committee approvals for VASCADE devices, where price-point sensitivity relative to manual compression alternatives exposes the company to budget pressure from integrated delivery networks and group purchasing organizations. The PerQseal Elite large-bore closure system has a premarket approval application currently under FDA review for an arterial indication in the United States.